Izzyring (Ethinylestradiol, Etonogestrel)

Ethinylestradiol and etonogestrel act on estrogen and progesterone receptors. By maintaining steady hormone levels, they suppress the hypothalamic‑pituitary‑ovarian axis, reducing the release of luteinizing hormone and follicle‑stimulating hormone, which prevents the development of a dominant follicle and thus ovulation. The progestin component also thickens cervical mucus, creating a physical barrier that hinders sperm penetration.

The dosing regimen for Izzyring is determined by the prescribing clinician. Typically, a single vaginal ring is inserted and left in place for a defined period, after which it is removed and a new ring is inserted according to the prescriber’s schedule. Patients should follow the specific instructions provided by their healthcare professional and not alter the duration without medical advice.

Izzyring is contraindicated during an existing pregnancy and should not be initiated in women who are pregnant. While limited data exist for breastfeeding, the hormonal content may pass into breast milk and could affect milk production or the infant; therefore, clinicians usually advise against use during lactation unless the benefits outweigh potential risks.

To order Izzyring from GNH India, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Compared with oral combined‑hormone pills, Izzyring offers a once‑monthly dosing schedule, eliminating the need for daily tablets and reducing the chance of missed doses. Unlike implants or intrauterine devices, the ring is removable at any time, providing rapid return to fertility. However, both oral pills and the ring share similar hormonal components and comparable side‑effect profiles.

Izzyring should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Do not expose the ring to extreme heat or humidity, and keep it out of reach of children. The product remains stable for the duration indicated on the packaging when stored under these conditions.

The ring is inserted into the upper vaginal fornix by the user or a healthcare professional, where it remains in place for the prescribed period, typically three weeks, followed by a ring‑free week during which withdrawal bleeding occurs. Insertion and removal should be performed with clean hands, and the user should avoid using tampons or douching while the ring is in place.

The most serious risks associated with Izzyring include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe hypertension, and rare hepatic tumors. Women presenting with unexplained leg pain, shortness of breath, sudden severe headache, or visual disturbances should seek immediate medical attention, as these symptoms may signal a serious adverse reaction.

Izzyring should not be used by women with a history of clotting disorders, uncontrolled hypertension, active liver disease, estrogen‑dependent tumors, known or suspected pregnancy, or those who smoke cigarettes and are over 35 years old. It is also contraindicated in individuals with known hypersensitivity to ethinylestradiol, etonogestrel, or any excipients in the ring.